Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Introduction: Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial (NCT02191891) investigated the combination of xentuzumab (an insulin-like growth factor-ligand neutralizing monoclonal antibody) and af...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Keunchil Park, MD, PhD, Daniel Shao Weng Tan, BSc, M.B.B.S., MRCP, Wu-Chou Su, MD, Byoung Chul Cho, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Chin-Chou Wang, MD, MS, Takashi Seto, MD, Dennis Chin-Lun Huang, MD, Helen Hayoun Jung, BS, RPh, Ming-Chi Hsu, PhD, Thomas Bogenrieder, MD, PhD, Chia-Chi Lin, MD, PhD
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2021-09-01
Seri Bilgileri:	JTO Clinical and Research Reports
Konular:	Afatinib EGFR tyrosine kinase inhibitor IGF NSCLC Xentuzumab
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2666364321000655
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Benzer Materyaller